NCT05858749View on ClinicalTrials.gov

A Study to Learn About the First and Later Lines of Medicines in Treating People With Metastatic Renal Cell Carcinoma (mRCC).

CompletedOBSERVATIONAL
Enrollment

494

Participants

Timeline

Start Date

June 20, 2022

Primary Completion Date

November 30, 2022

Study Completion Date

November 30, 2022

Conditions
Metastatic Renal Cell Carcinoma
Trial Locations (1)

10017

Pfizer Headquarters, New York

Sponsors

Lead Sponsor

Pfizer
All Listed Sponsors
lead

Pfizer

INDUSTRY

NCT05858749 - A Study to Learn About the First and Later Lines of Medicines in Treating People With Metastatic Renal Cell Carcinoma (mRCC). | Biotech Hunter | Biotech Hunter